Q: What is the Medicare Prescription Drug Inflation Rebate Program?  
The prescription drug law requires drug companies to pay a rebate if they raise their prices for certain drugs faster than the rate of inflation. This rebate is paid to Medicare and will be calculated and invoiced by the Centers for Medicare & Medicaid Services (CMS). The law establishes Medicare Part B prescription drug inflation rebates for single-source drugs and biologicals with prices increasing faster than the rate of inflation and provides for lower Part B beneficiary coinsurance on these drugs and biologicals. In addition, the law establishes Medicare Part D prescription drug inflation rebates for certain drugs and biologicals with prices increasing faster than the rate of inflation. Collectively, the program to implement these rebates is referred to as the Medicare Prescription Drug Inflation Rebate Program or the Inflation Rebate Program.

Q: How will this program improve Medicare?  
The Medicare Prescription Drug Inflation Rebate Program will lead to a stronger Medicare program for current and future beneficiaries and discourage runaway price increases by drug companies. The rebates paid by drug companies will be deposited in the Federal Supplementary Medical Insurance Trust Fund, which will help ensure long-term sustainability of the Medicare program for future generations.

Q: How will people with Medicare benefit from the Medicare Prescription Drug Inflation Rebate Program?  
The Medicare Prescription Drug Inflation Rebate Program may discourage drug companies from increasing their prices faster than the rate of inflation. Beginning April 1, 2023, people with Medicare started to see lower out-of-pocket costs for certain Part B drugs and biologicals with prices that have increased faster than the rate of inflation. For these drugs and biologicals, the beneficiary coinsurance is 20 percent of the inflation-adjusted payment amount, which is less than what the beneficiary would pay in coinsurance otherwise.

Q: What changed in the Medicare Prescription Drug Inflation Rebate Program between the 2023 revised guidance and this proposed rule?  
CMS is proposing to codify policies established in the revised guidance documents for the Part B Drug Inflation Rebate Program and the Part D Drug Inflation Rebate Program, both published December 14, 2023. In addition to codifying these policies, we are proposing new and revised policies for the Inflation Rebate Program in the Calendar Year (CY) 2025 Physician Fee Schedule (PFS) proposed rule. \(^1\)

For the Part B Drug Inflation Rebate Program, CMS proposes new policies to:
• Compare the payment amount in the quarterly pricing files published by CMS to the inflation-adjusted payment amount for a given quarter when determining whether the criteria for a coinsurance adjustment are met;
• Identify a benchmark quarter for drugs first approved or licensed by the FDA on or before December 1, 2020 but with a first marketed date after December 1, 2020;
• Remove 340B units for professional claims with dates of service during 2024 (in addition to 2023) submitted by Medicare suppliers associated with 340B covered entities;
• Establish a method and process for reconciliation of a rebate amount to account for revised information, calculation error, or misreporting, including the circumstances that may trigger such a reconciliation;

---

• Exclude units of refundable single dose container or single use package drugs subject to discarded drug refunds from the calculation of rebate amounts in the reconciliation process; and
• Establish a civil money penalty process for when a manufacturer of a Part B rebatable drug fails to pay the rebate amount in full by the payment deadline for such drug for such applicable calendar quarter.

For the Part D Drug Inflation Rebate Program, CMS proposes new policies to:
• Identify the payment amount benchmark period for a Part D rebatable drug in certain instances of missing Average Manufacturer Price (AMP);
• For claims with dates of service on or after January 1, 2026, establish a process to estimate the total number of units of a Part D rebatable drug for which a manufacturer provided a discount under the 340B Program and exclude such units from the total number of units used to calculate the total rebate amount for a Part D rebatable drug;
• Establish a method and process for reconciliation of a rebate amount to account for revised information, calculation error, or misreporting, including the circumstances that may trigger such a reconciliation; and
• Establish a civil money penalty process for when a manufacturer of a Part D rebatable drug fails to pay the rebate amount in full by the payment deadline for such drug for such applicable period.

To ensure consistency and uniformity in program implementation, CMS is proposing that the proposed provisions would apply with respect to applicable calendar quarters beginning on or after January 1, 2023 (for Part B) and applicable periods beginning on or after October 1, 2022 (for Part D).

CMS invites comments on these and other policies in the proposed rule. CMS also notes that these policies are subject to change based on public comments.

Q: Why is CMS using rulemaking instead of program guidance to make changes to the rebate program?
CMS is using rulemaking to make changes to the Inflation Rebate Program in 2025 because the IRA allows for the implementation of the Medicare Part D Drug Inflation Rebate Program through program instruction or other forms of program guidance only through 2024, and CMS seeks to set forth policies for both the Part B and Part D inflation rebates in regulations.

Q: Will CMS provide any additional information on implementation of the Inflation Rebate Program?
CMS may supplement this proposed rule with further program instruction to explain how these policies will be implemented or engage in further rulemaking.

Q: Will CMS continue to accept public input on the Medicare Prescription Drug Inflation Rebate Program?
Yes. Public feedback is critical to the success of the Inflation Rebate Program and implementation of all the Medicare provisions of the prescription drug law. CMS is using many tools to ensure interested parties’ voices are heard on implementation of the new program. CMS is engaging and will continue to engage interested parties through national stakeholder calls, quarterly strategic meetings, and monthly technical calls with CMS staff.

One tool CMS is using to solicit feedback from interested parties is notice-and-comment solicitation on newly proposed policies, as well as existing policies, for both the Medicare Part B and Part D Drug Inflation Rebate Programs.

In addition, previously CMS voluntarily sought comments during the comment period for the initial guidance. Commenters represented a wide range of views, including academic experts and thought leaders, consumer and patient organizations, data vendors/software technology entities, health plans, health care providers, health systems, individuals, drug companies, and pharmacies. CMS posted copies of the timely comment letters that CMS received on the Inflation Reduction Act website at https://www.cms.gov/inflation-reduction-act-and-medicare. CMS considered these comments when drafting the proposed rule and the revised Part B and Part D guidance.

These comments also may be considered for future implementation of the Inflation Rebate Program.

Q: How will CMS remove 340B units from the calculation of Part D rebates?
To fulfill the statutory requirement to remove 340B units from Part D inflation rebate calculations beginning on January 1, 2026, CMS proposes a new policy to remove units from the total number of units dispensed of a Part D rebatable drug for each applicable period based on a calculated percentage that reflects the portion of 340B purchasing relative to total sales. This “estimation

---

2 Under the Infrastructure Investment and Jobs Act of 2021 (P.L. 117-58), section 90004, manufacturers are required to provide a refund to CMS for certain discarded amounts from separately payable single-dose container or single-use package drugs beginning January 1, 2023.
percentage” represents total units purchased by covered entities under the 340B Drug Pricing Program as a share of total units sold. To determine the numerator of this percentage (i.e., the total number of units purchased under the 340B Program), CMS proposes to use data from the 340B Prime Vendor Program (PVP) (https://www.340bpvp.com/). To identify the denominator of the percentage (i.e., the total units sold), CMS proposes to use existing manufacturer reporting of unit sales to the Medicaid Drug Rebate Program (MDRP). CMS is soliciting comments on what other data sources may be available to calculate the numerator of the estimation percentage and is also considering certain adjustments to this percentage.

In response to feedback received on the initial Medicare Part D Drug Inflation Rebate Program Guidance, CMS is also soliciting comments on establishing a Medicare Part D claims data repository in future years of the Medicare Part D Drug Inflation Rebate Program. This approach would require that 340B covered entities submit certain data elements from 340B-identified Part D claims to the repository to allow CMS to identify 340B units to exclude from Part D drug inflation rebate calculations.

**Q: How is CMS calculating inflation rebates for drugs currently in shortage, facing a severe supply chain disruption, or likely to be in shortage?**

To calculate the reduction in the inflation rebate amount for a Part B or Part D rebatable drug currently in shortage, CMS will first determine the number of days such drug is described as “currently in shortage” on an FDA shortage list during the period for which the rebate is being assessed (i.e., calendar quarter for Part B or 12-month applicable period for Part D). CMS will then divide that number by the total number of days in the calendar quarter or applicable period. CMS will multiply that amount by a percentage that is decreased over time. The table below provides the reduction percentages for rebatable Part B or Part D drugs “currently in shortage” on an FDA shortage list.

For a Part B or Part D rebatable biosimilar or a generic Part D rebatable drug facing a severe supply chain disruption or a generic Part D rebatable drug likely to be in shortage, the drug company will be required to submit to CMS a request for a rebate reduction. The table below provides the reduction percentages for Part B and Part D rebatable biosimilars and generic Part D rebatable drugs when CMS determines there is a severe supply chain disruption and for generic Part D rebatable drugs that CMS determines are likely to be in shortage.

**Q: What is the process for a drug company to request a rebate reduction for a Part B or Part D rebatable biosimilar or Part D rebatable generic drug when there is a severe supply chain disruption or for a Part D rebatable generic drug that is likely to be in shortage?**

A drug company that seeks a reduction of the rebate amount for a Part B or Part D rebatable biosimilar or generic Part D rebatable drug when it believes there is a severe supply chain disruption or for a Part D rebatable generic drug that is likely to be in shortage will be required to submit to CMS a request for a reduction along with supporting documentation. To request a rebate reduction, a manufacturer should first email IRARebateandNegotiation@cms.hhs.gov to indicate its intention to submit a request for a reduction in the rebate amount. CMS will then provide the manufacturer with the relevant request form(s) and access to a secure submission process. The table below describes the process and deadlines for requesting a rebate reduction when a manufacturer believes there is a severe supply chain disruption or likely shortage.

In accordance with the Paperwork Reduction Act of 1995 (PRA), CMS has proposed an information collection request under the document identifier CMS–10858 addressing information and supporting documentation that must be submitted by a drug company requesting a rebate reduction under these policies, including the process steps for that submission. The proposed collection was published for a 30-day comment period in the June 3, 2024 Federal Register (89 FR 47563).

If the drug company submits a timely and complete request and CMS determines that a reduction should be granted based on its review of the request and supporting documentation, CMS will reduce the rebate amount by 75 percent for one year regardless of whether the drug subsequently goes on an FDA shortage list during that year. If a severe supply chain disruption or likely shortage is not resolved in the first year, the drug company may apply for an extension of the rebate reduction for a second year. Reductions for a severe supply chain disruption or likely shortage are limited to two consecutive years.
<table>
<thead>
<tr>
<th>Eligibility for a Rebate Reduction</th>
<th>Drug Shortage</th>
<th>Severe Supply Chain Disruption</th>
<th>Likely to be in Shortage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part B or Part D rebatable drug</td>
<td>Part B or Part D rebatable biosimilar or generic Part D rebatable drug for which a drug company submits a request to CMS</td>
<td>Generic Part D rebatable drug for which a drug company submits a request to CMS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Process to Request a Rebate Reduction</th>
<th>Drug Shortage</th>
<th>Severe Supply Chain Disruption</th>
<th>Likely to be in Shortage</th>
</tr>
</thead>
<tbody>
<tr>
<td>No request required. CMS will monitor the FDA shortage lists</td>
<td>A drug company must email CMS and submit a Severe Supply Chain Disruption Rebate Reduction Request, or Extension Request, with supporting documentation in accordance with the proposed information collection request which is currently going through the Paperwork Reduction Act approval process under the document identifiers CMS-10858</td>
<td>A drug company must email CMS and submit a Likely to be in Shortage Rebate Reduction Request, or Extension Request, with supporting documentation in accordance with the proposed information collection request which is currently going through the Paperwork Reduction Act approval process under the document identifiers CMS-10858</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deadline for Initial Request</th>
<th>Drug Shortage</th>
<th>Severe Supply Chain Disruption</th>
<th>Likely to be in Shortage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 60 calendar days from the first day that the natural disaster or other unique or unexpected event occurred or began for a natural disaster or other unique or unexpected event occurring on or after August 2, 2024 for a Part B or Part D rebatable biosimilar or generic Part D rebatable drug</td>
<td>At least 60 calendar days before the start of the second applicable period or fifth calendar quarter in which the Part B or Part D rebatable biosimilar or generic Part D rebatable drug continues to be affected by the severe supply chain disruption(^3)</td>
<td>Before the start of the applicable period in which the generic Part D rebatable drug is likely to be in shortage</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deadline for Extension Request</th>
<th>Drug Shortage</th>
<th>Severe Supply Chain Disruption</th>
<th>Likely to be in Shortage</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least 60 calendar days before the start of the second applicable period in which the generic Part D rebatable drug is likely to be in shortage</td>
<td>At least 60 calendar days before the start of the second applicable period in which the generic Part D rebatable drug is likely to be in shortage</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Reduction</th>
<th>Drug Shortage</th>
<th>Severe Supply Chain Disruption</th>
<th>Likely to be in Shortage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indefinite for as long as drug is “currently in shortage” on an FDA shortage list; the reduction is based on the amount of time a drug is “currently in shortage” and decreases over time.</td>
<td>One year; drug company may request an extension of the reduction for an additional year for up to two consecutive years total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^3\) In cases where the initial request for a generic Part D rebatable drug or Part D rebatable biosimilar is made less than 60 calendar days before the end of an applicable period such that the initial rebate reduction applied to the next applicable period rather than the applicable period in which the event that caused the severe supply chain disruption occurred or began, the Extension Request must be submitted at least 60 calendar days prior to the end of that next applicable period in which the initial reduction applied.
<table>
<thead>
<tr>
<th>Percent Reduction in Rebate Owed</th>
<th>Part B or Part D rebatable drug other than a plasma-derived product or Part D rebatable generic drug</th>
<th>Part B or Part D plasma-derived product or Part D rebatable generic drug</th>
<th>Part B or Part D rebatable biosimilar or Part D rebatable generic drug</th>
<th>Part D rebatable generic drug</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First year</strong></td>
<td>25%</td>
<td>75%</td>
<td>75%</td>
<td>75%</td>
</tr>
<tr>
<td><strong>Second year</strong></td>
<td>10%</td>
<td>50%</td>
<td>75%</td>
<td>75%</td>
</tr>
<tr>
<td><strong>Subsequent years</strong></td>
<td>2%</td>
<td>25%</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Application of Reduction\(^4\)**

For a Part B rebatable drug, CMS will apply the rebate reduction to all of the NDCs under the relevant HCPCS code(s) if any NDC-10 assigned to the HCPCS code(s) is currently in shortage\(^5\).

For a Part D rebatable drug, CMS will apply the rebate reduction to the entire Part D rebatable drug at the NDC-9 level if any NDC-10 for a Part D rebatable drug is currently in shortage.

For a Part B rebatable biosimilar, CMS will apply the rebate reduction to all the NDC-11s under the relevant HCPCS code if CMS grants a drug company’s request for an NDC-11.

For a generic Part D rebatable drug, CMS will apply the rebate reduction to the entire generic Part D rebatable drug at the NDC-9 level if CMS grants a drug company’s request for an NDC-11.

For a generic Part D rebatable drug, CMS will apply the rebate reduction to the entire generic Part D rebatable drug at the NDC-9 level if CMS grants a drug company’s request for an NDC-11.

---

\(^4\) Although the NDC information used for rebate reductions for drugs currently in shortage are applied based on the NDC-10 level, a drug company requesting a rebate reduction based on a severe supply chain disruption or likely shortage should submit information at the NDC-11 level.

\(^5\) For the purposes of this Fact Sheet, CMS uses the term “currently in shortage” to refer to Part B or Part D rebatable drugs that are in the status of “currently in shortage” on the CDER shortage list, as well as biological products listed on CBER’s current shortages list.

Note: Generic drugs are not Part B rebatable drugs. The scope of generic drugs subject to Part D drug inflation rebates is limited to sole-source generic drugs. Multi-source generic drugs are not Part D rebatable drugs.
Q: How and when will CMS invoice manufacturers for inflation rebate amounts?
CMS proposes to establish a standard method and process to issue rebate reports to manufacturers. This method and process may include use of an online portal. CMS will first provide a Preliminary Rebate Report and a Suggestion of Error period for manufacturers to review the preliminary rebate amount and identify certain mathematical errors. After the Suggestion of Error period, CMS will provide the Rebate Report, which will include the rebate amount. The rebate amount may be reduced for drugs currently in shortage, facing a severe supply chain disruption, or likely to be in shortage, or adjusted in the program's reconciliation process.

For Part B inflation rebates for all calendar quarters in 2023 and 2024, CMS will invoice manufacturers no later than September 30, 2025. For calendar quarters in 2025 and beyond, CMS will invoice manufacturers for Part B rebates no later than 6 months after the end of the applicable calendar quarter.

For Part D inflation rebates for the 12-month applicable periods beginning October 1, 2022 and October 1, 2023, CMS will invoice manufacturers no later than December 31, 2025 for both applicable periods. For applicable periods beginning October 1, 2024 and beyond, CMS will invoice manufacturers for Part D rebates no later than 9 months after the end of each applicable period.

Q: What would be reconciled?
CMS proposes to reconcile the rebate amount for Part B and Part D inflation rebates. For Part B inflation rebates, CMS proposes to reconcile the rebate amount to include updated information about key data elements included in the calculation of the rebate amount. Twelve months after the receipt of the Rebate Report, CMS will provide to the manufacturers a reconciled rebate amount with restatements, as applicable, of the data elements included in the rebate calculation. The updated calculation will be the reconciled rebate amount.

For Part D inflation rebates, CMS proposes two regular reconciliations of the rebate amount to occur 12 months and 36 months after the receipt of the Rebate Report. In these reconciliations, CMS will provide to the manufacturers restatements, as applicable, of the data elements included in the rebate calculation. The updated calculation will be the reconciled rebate amount.

Q: Why is Part D reconciliation occurring at 12 months and 36 months?
CMS is proposing to conduct two Part D reconciliations to ensure there is enough time to capture the relevant data for an accurate rebate amount. The 12-month reconciliation would provide sufficient time to capture the majority of updates to the data that encompass the rebate amount. The 36-month reconciliation would be sufficient to capture the remainder of the run-out for MDRP AMP restatements.

Q: Why is there a reconciliation process?
Per statute, CMS must provide a method and process to adjust the calculation of the rebate amount for a Part D rebatable drug for an applicable period if CMS determines such an adjustment is necessary based on revisions to the number of units dispensed submitted by a PDP sponsor of a prescription drug plan or an MA organization offering an MA-PD plan. The statute specifies that, CMS must reconcile any underpayments in the rebate amount paid by the manufacturer of the applicable Part D rebatable drug due to such an adjustment. To fulfill this statutory obligation and to address the accuracy of the rebate amount, CMS proposes to conduct regular reconciliations under the Part D Drug Inflation Rebate Program. CMS also believes conducting a reconciliation for the Part B Drug Inflation Rebate Program is important in ensuring the accuracy of the rebate amount and for programmatic alignment with the Part D Drug Inflation Rebate Program.

Q: What are the key dates for implementation of this program?

- **October 1, 2022** – The start of the first 12-month applicable period for which drug companies will be required to pay rebates to Medicare if their prices for certain Part D drugs increase faster than the rate of inflation over the 12-month period.
- **December 20, 2022** – CMS issued its first inflation rebate guidance for Medicare providers and suppliers regarding reporting the 340B modifier for the Part B inflation rebates.
- **January 1, 2023** – The start of the first quarter for which drug companies will be required to pay rebates to Medicare if prices for certain Part B drugs increase faster than the rate of inflation.
More information on the Medicare Prescription Drug Inflation Rebate Program: